About GondolaBio
GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.
Who You Are
A translational scientist who bridges discovery and early clinical development, designing and implementing biomarker and pharmacodynamic (PD) strategies that inform decision-making in IND-enabling and Phase 1/2 studies. Hands-on and execution-focused, with a track record of turning preclinical hypotheses into fit-for-purpose assays that perform in the clinic. Scientifically rigorous and detail-oriented, with a strong foundation in biochemistry and assay development. A collaborative, pragmatic communicator who partners across discovery, development, and external teams to deliver high-quality, decision-ready data, and who can clearly articulate experimental rationale, assay performance, and clinical relevance.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.